Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Spinal and Bulbar Muscular Atrophy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Spinal and Bulbar Muscular Atrophy. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Spinal and Bulbar Muscular Atrophy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 2 / Phase 3: 1.

Research is led by National Institute of Neurological Disorders and Stroke (NINDS) (1), Gianni Soraru (1), Masahisa Katsuno (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Placebo (drug, 2 trials), followed by Clenbuterol, Mexiletine hydrochloride.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Spinal and Bulbar Muscular Atrophy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04944940

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Background: SBMA is an inherited chronic disease. It affects males in mid to late adulthood. It causes slowly progressive weakness of muscles and hand tremors. Researchers want...

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)Enrolling: 701 location
RECRUITINGPhase 2NCT06169046

A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy

There is no cure to arrest or delay SBMA progression. It is estimated that \~1000 individuals are affected by SBMA in Italy at any given time (prevalence: 1.5/100000) with an...

Sponsor: Gianni SoraruEnrolling: 901 location
RECRUITINGPhase 2 / Phase 3NCT06862596

Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

The purpose of this clinical trial is to evaluate the efficacy and safety of mexiletine hydrochloride in patients with spinal and bulbar muscular atrophy. The main questions it...

Sponsor: Masahisa KatsunoEnrolling: 685 locations

Frequently Asked Questions

There are currently 3 clinical trials for Spinal and Bulbar Muscular Atrophy, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Spinal and Bulbar Muscular Atrophy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Spinal and Bulbar Muscular Atrophy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.